Protara Q4 net loss widens on higher R&D spend

Protara Therapeutics

10/03/2026 12:07

Overview

Biotechnology firm's Q4 net loss was $17.3 mln, driven by increased R&D expenses

Company completed $86 mln public offering, cash supports operations into 2028

Outlook

Protara to provide regulatory update for TARA-002 in LMs in 1H 2026

Result Drivers

FINANCIAL POSITION - Completed $86 mln public offering, cash supports operations into 2028

Company press release: ID:nGNX10t3qG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.37
Q4 Net Income
-$17.31 mln
Q4 Income from Operations
-$19.08 mln
Q4 Operating Expenses
$19.08 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Protara Therapeutics Inc is $25.00, about 334.8% above its March 9 closing price of $5.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)